NICE Single Technology Appraisal Guidance No 207 – Temsirolimus
for the treatment of relapsed or refractory mantle cell lymphoma
(terminated appraisal)
This NICE was published today, 27 October 2010.
The web reference for the appraisal and other related documents is:
http://guidance.nice.org.uk/TA207
The guidance states that NICE is unable to
recommend the use in the NHS of temsirolimus for the treatment of
relapsed or refractory mantle cell lymphoma because no evidence
submission was received from the manufacturer or sponsor of the
technology.
NHSScotland should note that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS boards should adhere to the advice of the
Scottish Medicines Consortium.
3. The Scottish Medicines Consortium (SMC)
published a Statement of Advice on this medication for this
indication in April 2010 (617/10). This stated that:
In the absence of a submission from the holder
of the marketing authorisation, temsirolimus is not recommended for
use within NHSScotland.
If you need further assistance, please contact
Eleanor Brownlee in
the first instance tel 0141 225 6873
Published Date: 27 October 2010
